Gastro-esophageal Reflux Disease (GERD) Completed Phase 3 Trials for Tegaserod (DB01079)

Also known as: Gastroesophageal Reflux Disease / Gastro-esophageal Reflux Disease / GERD / GERD Gastroesophageal Reflux Disease / Gastro-Oesophageal Reflux Disease / Gastrooesophageal reflux disease / GERD (Gastroesophageal Reflux Disease) / Esophageal Reflux / GERD - Gastro-Esophageal Reflux Disease / Gastroesophageal Reflux Disease (GERD) / Gastro-esophageal Reflux Diseases / Oesophageal reflux / Esophagitis / Gastrooesophageal reflux / Gastroesophageal reflux / Esophageal reflux NOS

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00171483Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).Treatment
NCT00171418Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).Treatment